Vaxcyte (PCVX) EBT (2019 - 2026)
Vaxcyte (PCVX) posted quarterly EBT of -$322.9 million for Q1 2026, down 113.95% year-over-year from $2.3 billion in Q1 2025, and up 14.61% quarter-over-quarter from -$378.2 million in Q4 2025.
Vaxcyte (PCVX) EBT (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported EBT for 8 consecutive years, with -$322.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 113.95% year-over-year to -$322.9 million; the TTM figure through Mar 2026 stood at -$1.3 billion (down 160.47% YoY), while the FY2025 annual figure was -$1.4 billion, down 60.03% from the prior year.
- EBT rose to -$322.9 million in Q1 2026 per PCVX's latest filing, from -$378.2 million in the prior quarter.
- Across five years, EBT topped out at -$79.9 million in Q4 2022 and bottomed at -$455.9 million in Q1 2024.
- Historically, EBT has averaged -$224.2 million across 5 years, with a median of -$179.1 million in 2023.
- Annual changes were most pronounced in 2022 — EBT sank 380.33% — and 2025, when it surged 66.89%.
- Vaxcyte's EBT stood at -$79.9 million in 2022, then sank by 124.05% to -$179.1 million in 2023, then surged by 34.51% to -$117.3 million in 2024, then sank by 222.39% to -$378.2 million in 2025, then advanced by 14.61% to -$322.9 million in 2026.
- Business Quant data shows PCVX's EBT at -$322.9 million in Q1 2026, -$378.2 million in Q4 2025, and -$331.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -477.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -477.96 Mn |
| Mar 31, 2026 | -322.95 Mn |
| Dec 31, 2025 | -378.18 Mn |
| Sep 30, 2025 | -331.15 Mn |
| Jun 30, 2025 | -316.12 Mn |
| Mar 31, 2025 | -150.94 Mn |
| Dec 31, 2024 | -117.31 Mn |
| Sep 30, 2024 | -115.48 Mn |
| Jun 30, 2024 | -133.95 Mn |
| Mar 31, 2024 | -455.93 Mn |
| Dec 31, 2023 | -179.11 Mn |
| Sep 30, 2023 | -343.44 Mn |
| Jun 30, 2023 | -316.10 Mn |
| Mar 31, 2023 | -207.79 Mn |
| Dec 31, 2022 | -79.94 Mn |
| Sep 30, 2022 | -131.53 Mn |
| Jun 30, 2022 | -113.54 Mn |
| Mar 31, 2022 | -118.57 Mn |
| Dec 31, 2021 | -29.75 Mn |
| Sep 30, 2021 | -120.32 Mn |